The Dermatological Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Dermatological Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dermatological Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dermatological Disorders and features dormant and discontinued products.
GlobalData tracks 31 drugs in development for Dermatological Disorders by 26 companies/universities/institutes. The top development phase for Dermatological Disorders is preclinical with 12 drugs in that stage. The Dermatological Disorders pipeline has 28 drugs in development by companies and three by universities/ institutes. Some of the companies in the Dermatological Disorders pipeline products market are: University of Wisconsin Madison, Pfizer and Maruho.
The key targets in the Dermatological Disorders pipeline products market include Toll-Llike Receptor 7, Vitamin D3 Receptor, and Transforming Growth Factor Beta.
The key mechanisms of action in the Dermatological Disorders pipeline product include Toll-Llike Receptor 7 Agonist with two drugs in Phase I. The Dermatological Disorders pipeline products include six routes of administration with the top ROA being Topical and nine key molecule types in the Dermatological Disorders pipeline products market including Small Molecule, and Monoclonal Antibody.
Dermatological Disorders overview
Dermatological disorders are diseases or conditions that affect the skin, hair, or nails. They can have various causes, symptoms, and treatments. Some of the most common dermatological disorders are acne, eczema, psoriasis, rosacea, and warts. Dermatologists are doctors who specialize in diagnosing and treating these disorders. Dermatological disorders can affect the appearance, function, and quality of life of the patients. Some of them can also increase the risk of skin cancer or other complications.
For a complete picture of Dermatological Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
